Tirzepatide and semaglutide are the two leading incretin-based therapies for type 2 diabetes and obesity. Tirzepatide (Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist; semaglutide (Ozempic, Wegovy, and Rybelsus) is a GLP-1 receptor agonist. In head-to-head trials, tirzepatide consistently produces greater A1C reduction and weight loss. Semaglutide has more mature cardiovascular outcome data and the only oral incretin formulation. Both work well for most patients, and choice depends on goals, cardiovascular profile, route preference, and cost.
Side-by-Side Comparison
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Brand names | Mounjaro (T2D), Zepbound (obesity) | Ozempic (T2D), Wegovy (obesity), Rybelsus (oral T2D) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 single agonist |
| Routes available | Subcutaneous injection only | Subcutaneous injection and oral tablet |
| Approval year | May 2022 (Mounjaro); Nov 2023 (Zepbound) | Dec 2017 (Ozempic); June 2021 (Wegovy); Sept 2019 (Rybelsus) |
| Dose range | 2.5 to 15 mg weekly | 0.25 to 2.4 mg weekly (injectable); 3 to 14 mg daily (oral) |
| A1C reduction (T2D, max dose) | ~2.3 percentage points | ~2.0 percentage points |
| Weight loss (T2D) | ~11–12 kg / ~12% body weight | ~6–7 kg / ~6–7% body weight |
| Weight loss (obesity) | ~20% body weight (SURMOUNT-1) | ~15% body weight (STEP 1) |
| CV risk reduction indication | Pending (SURPASS-CVOT, SURMOUNT-MMO) | Yes (SUSTAIN-6 for T2D, SELECT for obesity) |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
| List price/month | ~$1,000–$1,070 | ~$970–$1,350 |
What Each One Is
Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist. It activates both incretin receptors at potencies designed to maximize insulin secretion, adipose tissue insulin sensitivity, and appetite suppression. The same molecule is marketed under two brand names — Mounjaro for type 2 diabetes (approved May 2022) and Zepbound for chronic weight management (approved November 2023). Read the tirzepatide overview.
Semaglutide activates the GLP-1 receptor with high affinity and has a half-life of approximately one week, enabling weekly subcutaneous dosing. The same molecule is marketed as Ozempic (lower doses for type 2 diabetes), Wegovy (higher doses for weight management), and Rybelsus (oral tablet for type 2 diabetes). Read the semaglutide overview.
Head-to-Head Trials
SURPASS-2 (type 2 diabetes) — Tirzepatide vs. semaglutide 1 mg, 40 weeks, 1,879 patients on metformin.
| Outcome | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Semaglutide 1 mg |
|---|---|---|---|---|
| A1C reduction | 2.01% | 2.24% | 2.30% | 1.86% |
| Weight loss (kg) | 7.6 | 9.3 | 11.2 | 5.7 |
| A1C below 5.7% | 27% | 40% | 46% | 19% |
SURMOUNT-5 (obesity) — Tirzepatide vs. semaglutide 2.4 mg, 72 weeks, 751 patients with obesity without diabetes.
| Outcome | Tirzepatide (10 or 15 mg) | Semaglutide 2.4 mg |
|---|---|---|
| Body weight loss | ~20.2% | ~13.7% |
| Patients ≥ 15% loss | ~65% | ~40% |
| Patients ≥ 25% loss | ~32% | ~16% |
Pharmacology Differences
- Tirzepatide is a synthetic 39-amino-acid peptide engineered to bind both GIP and GLP-1 receptors. It has weaker affinity for GLP-1 receptor than native GLP-1, but its dual mechanism amplifies metabolic effects.
- Semaglutide is a synthetic 31-amino-acid analog of human GLP-1, with modifications that extend half-life and improve receptor binding.
- Both have weekly half-lives suitable for once-weekly subcutaneous dosing.
- Semaglutide additionally has an oral formulation (Rybelsus) made possible by an absorption enhancer (SNAC); no oral tirzepatide is currently approved.
Cardiovascular Outcomes
Semaglutide — SUSTAIN-6 (2016) showed 26 percent reduction in major adverse cardiovascular events in T2D plus established CVD. SELECT (2023) extended the benefit to high-dose semaglutide in obesity with established CVD, showing 20 percent MACE reduction. Both translate to formal cardiovascular risk reduction indications for Ozempic and Wegovy.
Tirzepatide — SURPASS-CVOT and SURMOUNT-MMO trials are ongoing. Preliminary data suggest cardiovascular safety but no formal indication yet. Some experts expect cardiovascular benefit to be at least comparable to semaglutide based on shared GLP-1 mechanism, but formal trial results are awaited.
Other Indications and Trials
- Tirzepatide (Zepbound) — Approved for obstructive sleep apnea in obesity (SURMOUNT-OSA)
- Tirzepatide — SUMMIT (HFpEF) and SURPASS-CKD studies in progress
- Semaglutide — Approved for heart failure with preserved ejection fraction in obesity (STEP-HFpEF); FLOW showed 24% reduction in kidney/CV events in T2D + CKD
- Both being studied for MASH/NASH, Alzheimer disease, and substance use disorders
Brand and Indication Map
| Drug | Brand | Indication | Route |
|---|---|---|---|
| Tirzepatide | Mounjaro | Type 2 diabetes | SC weekly |
| Tirzepatide | Zepbound | Obesity; OSA in obesity | SC weekly |
| Semaglutide | Ozempic | Type 2 diabetes; CV risk reduction in T2D + CVD | SC weekly |
| Semaglutide | Wegovy | Obesity; CV risk reduction in obesity + CVD; HFpEF in obesity | SC weekly |
| Semaglutide | Rybelsus | Type 2 diabetes | Oral daily |
Side Effects (Both)
- Nausea — most common, peaks after each dose increase
- Vomiting, diarrhea, constipation
- Abdominal pain
- Decreased appetite
- Fatigue, headache
- Injection site reactions
- Gallbladder issues
- Pancreatitis (rare)
- Acute kidney injury (typically dehydration-driven)
- Hypoglycemia when combined with insulin or sulfonylureas
- Boxed warning for thyroid C-cell tumors
When to Choose Tirzepatide
- Greater A1C reduction or weight loss is desired
- Inadequate response to semaglutide at maximum dose
- Obstructive sleep apnea in obesity (specific Zepbound indication)
- Cash-pay patient — Zepbound vials through LillyDirect are notably cheaper than other branded GLP-1 options
When to Choose Semaglutide
- Established cardiovascular disease — formal CV risk reduction indication
- Heart failure with preserved ejection fraction (Wegovy)
- Chronic kidney disease in type 2 diabetes (FLOW trial)
- Patient prefers oral over injection — Rybelsus is the only oral option
- Longer real-world experience preferred
Cost and Access
Both drug families list at roughly $1,000 to $1,350 per month, varying by brand and dose. Insurance coverage differs by formulary. Manufacturer savings cards from both Eli Lilly and Novo Nordisk can reduce commercial copays. Eli Lilly offers Zepbound vials through LillyDirect at $350-$700/month cash, which Novo Nordisk has not matched for Wegovy.
Lifestyle Pairing
Both medications work best alongside diet and activity changes. Read about treatment overview and diet strategies.
The Bottom Line
Tirzepatide produces greater A1C reduction and weight loss than semaglutide in head-to-head trials, owing to its dual GIP/GLP-1 mechanism. Semaglutide has more mature cardiovascular outcome data with formal CV risk reduction indications in type 2 diabetes and obesity, and is the only incretin with an oral formulation (Rybelsus). Side effect profiles are similar. Cost is comparable, with Zepbound’s cash-pay vial option offering a lower price point. Talk to your doctor about which fits your goals — A1C targets, weight loss, cardiovascular profile, route preference, and insurance coverage all matter.
